Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens

Nature Reviews Drug Discovery

Volumn 14, Issue 7, 2015, Pages 487-498

  Childs, Richard W ^a   Carlsten, Mattias ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CETUXIMAB; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; IPH 2101; LENALIDOMIDE; LIRILUMAB; MONOCLONAL ANTIBODY; NICOTINAMIDE; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROTEASOME INHIBITOR; RECOMBINANT ALPHA 1,3 FUCOSYLTRANSFERASE VI; RECOMBINANT INTERLEUKIN 12; RITUXIMAB; SELENITE; SINGLE CHAIN RECOMBINANT INTERLEUKIN 15; SOLUBLE INTERLEUKIN 15RALPHA; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT; CYTOTOXIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BISPECIFIC KILLER ENGAGER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL ACTIVITY; CELL EXPANSION; CELL HOMING; CELL MANIPULATION; CELL MIGRATION; CELL PROLIFERATION; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CYTOTOXICITY; DEGRANULATION; DRUG APPROVAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EX VIVO STUDY; GENETIC MANIPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; INNATE IMMUNITY; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOMA; MESOTHELIOMA; MOLECULE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; TRISPECIFIC KILLER ENGAGER; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; BIOLOGICAL PRODUCTS; CYTOTOXINS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84934441505     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4506     Document Type: Review

References (115)

1. Moretta, L., Ciccone, E., Mingari, M. C., Biassoni, R., Moretta, A. Human natural killer cells: origin, clonality, specificity, and receptors. Adv. Immunol. 55, 341-380 (1994).
2. Gregoire, C. et al. The trafficking of natural killer cells. Immunol. Rev. 220, 169-182 (2007).
3. Herberman, R. B., Nunn, M. E., Holden, H. T., Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16, 230-239 (1975).
4. Herberman, R. B., Nunn, M. E., Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 16, 216-229 (1975).
5. Kiessling, R., Klein, E., Pross, H., Wigzell, H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5, 117-121 (1975).
6. Kiessling, R., Klein, E., Wigzell, H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112-117 (1975).
7. Foley, B. et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119, 2665-2674 (2012).
8. Foley, B. et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C+ NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J. Immunol. 189, 5082-5088 (2012).
9. Bryceson, Y. T., Long, E. O. Line of attack: NK cell specificity and integration of signals. Curr. Opin. Immunol. 20, 344-352 (2008).
10. Kre, K. in Mechanisms of Cytotoxicity by NK Cells (eds Callewaert, D., Herberman, R. B.) 81-91 (Academis Press., 1985).
11. Ljunggren, H. G., Karre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11, 237-244 (1990).
12. Anfossi, N. et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331-342 (2006).
13. Kim, S. et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436, 709-713 (2005).
14. Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
15. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
16. Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492 (1985).
17. West, W. H. et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316, 898-905 (1987).
18. Curti, A. et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273-3279 (2011).
19. Geller, M. A. et al. A Phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13, 98-107 (2011).
20. Ito, S. et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol. Ther. 22, 1388-1395 (2014).
21. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529-533 (2012).
22. Leclercq, G., Debacker, V., de Smedt, M., Plum, J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 184, 325-336 (1996).
23. Pillet, A. H., Bugault, F., Theze, J., Chakrabarti, L. A., Rose, T. A programmed switch from IL-15-to IL-2-dependent activation in human NK cells. J. Immunol. 182, 6267-6277 (2009).
24. Pillet, A. H., Theze, J., Rose, T. Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes. Hum. Immunol. 72, 1013-1017 (2011).
25. Carson, W. E. et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99, 937-943 (1997).
26. Berger, C. et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114, 2417-2426 (2009).
27. Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74-82 (2015).
28. Cooley, S. et al. Recombinant human IL-15 promotes in vivo expansion of adoptively transferred NK cells in a first-in-human Phase I dose escalation study in patients with AML. Blood 615, 894 (2012).
29. Miller, J. S. Therapeutic applications: natural killer cells in the clinic. Hematol. Am. Soc. Hematol. Educ. Program 2013, 247-253 (2013).
30. Dubois, S., Patel, H. J., Zhang, M., Waldmann, T. A., Muller, J. R. Preassociation of IL-15 with IL-15R ?-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J. Immunol. 180, 2099-2106 (2008).
31. Han, K. P. et al. IL-15:IL-15 receptor superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804-810 (2011).
32. Wu, Z., Xu, Y. IL-15R ?-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. J. Mol. Cell. Biol. 2, 217-222 (2010).
33. Steel, J. C., Waldmann, T. A., Morris, J. C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33, 35-41 (2012).
34. Pistoia, V., Cocco, C., Airoldi, I. Interleukin-12 receptor ?2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J. Clin. Oncol. 27, 4809-4816 (2009).
35. Kobayashi, M. et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845 (1989).
36. Lehmann, D. et al. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential. PLoS ONE 9, e87131 (2014).
37. Allavena, P. et al. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 84, 2261-2268 (1994).
38. Gollob, J. A. et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN induction is associated with clinical response. Clin. Cancer Res. 6, 1678-1692 (2000).
39. Gollob, J. A. et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21, 2564-2573 (2003).
40. Trudeau, C. et al. A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon and signal transducer and activator of transcription in healthy subjects. J. Clin. Pharmacol. 45, 649-658 (2005).
41. Robertson, M. J. et al. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin. Cancer Res. 8, 3383-3393 (2002).
42. Basile, L. A., Gallaher, T. K., Shibata, D., Miller, J. D., Douer, D. Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J. Transl. Med. 6, 26 (2008).
43. Gokhale, M. S. et al. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp. Hematol. Oncol. 3, 11 (2014).
44. Zhu, D., Corral, L. G., Fleming, Y. W., Stein, B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol. Immunother. 57, 1849-1859 (2008).
45. Gorgun, G. et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116, 3227-3237 (2010).
46. Davies, F. E. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216 (2001).
47. Reddy, N. et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 140, 36-45 (2008).
48. Hayashi, T. et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 128, 192-203 (2005).
49. Lagrue, K., Chopra, R., Davis, D. M. The immunomodulatory drug Lenalidomide alters the threshold for NK cell activation and augments NK cell effector functions. Immunology 140 (Suppl.1), 71 (2013).
50. Berg, S. L. et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J. Clin. Oncol. 29, 316-323 (2011).
51. Chanan-Khan, A. A. et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br. J. Haematol. 155, 457-467 (2011).
52. Eve, H. E. et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br. J. Haematol. 159, 154-163 (2012).
53. Wolschke, C. et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a Phase I/II dose-finding study. Exp. Hematol. 41, 134-142.e3 (2013).
54. Keir, M. E., Butte, M. J., Freeman, G. J., Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
55. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
56. MacFarlane, A. W. 4th et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol. Res. 2, 320-331 (2014).
57. Wiesmayr, S. et al. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur. J. Immunol. 42, 541-550 (2012).
58. Benson, D. M. Jr et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010).
59. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
60. Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase 1 trial. Lancet 384, 1109-1117 (2014).
61. Weber, J. S. et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J. Clin. Oncol. 31, 4311-4318 (2013).
62. Benson, D. M. Jr et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118, 6387-6391 (2011).
63. Romagne, F. et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114, 2667-2677 (2009).
64. Sola, C. et al. Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc. Natl Acad. Sci. USA 106, 12879-12884 (2009).
65. Vahlne, G. et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur. J. Immunol. 40, 813-823 (2010).
66. Korde, N. et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99, e81-e83 (2014).
67. Maloney, D. G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366, 2008-2016 (2012).
68. Wu, J. et al. A novel polymorphism of Fc?RIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100, 1059-1070 (1997).
69. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc?RIIIa gene. Blood 99, 754-758 (2002).
70. Weng, W. K., Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
71. Pander, J. et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur. J. Cancer 46, 1829-1834 (2010).
72. Tarek, N. et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122, 3260-3270 (2012).
73. Kim, D. H. et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108, 2720-2725 (2006).
74. Gleason, M. K. et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674-2684 (2012).
75. Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 × 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844-3855 (2013).
76. Thorburn, A. Death receptor-induced cell killing. Cell. Signal. 16, 139-144 (2004).
77. Lundqvist, A., Yokoyama, H., Smith, A., Berg, M., Childs, R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113, 6120-6127 (2009).
78. Merino, D. et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell. Biol. 26, 7046-7055 (2006).
79. Vales-Gomez, M., Chisholm, S. E., Cassady-Cain, R. L., Roda-Navarro, P., Reyburn, H. T. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 68, 1546-1554 (2008).
80. Wennerberg, E. et al. Doxorubicin sensitizes human tumor cells to NK cell-and T-cell-mediated killing by augmented TRAIL receptor signaling. Int. J. Cancer 133, 1643-1652 (2013).
81. Diermayr, S. et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111, 1428-1436 (2008).
82. Armeanu, S. et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329 (2005).
83. Skov, S. et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65, 11136-11145 (2005).
84. Lundqvist, A. et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66, 7317-7325 (2006).
85. Bandura, L., Drukala, J., Wolnicka-Glubisz, A., Bjornstedt, M., Korohoda, W. Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells. Biochem. Cell Biol. 83, 196-211 (2005).
86. Husbeck, B., Nonn, L., Peehl, D. M., Knox, S. J. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66, 218-225 (2006).
87. Kandas, N. O., Randolph, C., Bosland, M. C. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr. Cancer 61, 251-264 (2009).
88. Enqvist, M. et al. Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells. J. Immunol. 187, 3546-3554 (2011).
89. Shi, J. et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 143, 641-653 (2008).
90. Childs, R. W., Berg, M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematol. Am. Soc. Hematol. Educ. Program 2013, 234-246 (2013).
91. Fujisaki, H., Kakuda, H., Imai, C., Mullighan, C. G., Campana, D. Replicative potential of human natural killer cells. Br. J. Haematol. 145, 606-613 (2009).
92. Garg, T. K. et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 97, 1348-1356 (2012).
93. Imai, C., Iwamoto, S., Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376-383 (2005).
94. Lapteva, N. et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 14, 1131-1143 (2012).
95. Liu, Y. et al. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin. Cancer Res. 19, 2132-2143 (2013).
96. Zhang, H. et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J. Immunother. 34, 187-195 (2011).
97. Denman, C. J. et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).
98. Berg, M. et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11, 341-355 (2009).
99. Miller, J. S. et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol. Blood Marrow Transplant 20, 1252-1257 (2014).
100. Frei, G. et al. Nicotinamide, a form of vitamin B3, promotes expansion of natural killer cells that display increased in vivo survival and cytotoxic activity. Blood 703, 4035 (2011).
101. Frei, G. et al. Improved homing to bone marrow, spleen and lung of adoptively infused NK cells expanded ex vivo with the small molecule nicotinamide using feeder-free conditions. Blood 122, 897 (2013).
102. Li, L. et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 17, 147-154 (2010).
103. Shimasaki, N. et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14, 830-840 (2012).
104. Carlsten, M. et al. Clinical-grade mRNA electroporation of NK cells: a novel and highly efficient method to genetically reprogram human NK cells for cancer immunotherapy. Blood 801, 2153 (2014).
105. Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917-927 (2014).
106. Xia, L., McDaniel, J. M., Yago, T., Doeden, A., McEver, R. P. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 104, 3091-3096 (2004).
107. Onishi, T. et al. Forced fucosylation with ASC-101 enhances the binding of ex vivo expanded human NK cells to E-selectin: a novel method to improve the homing of adoptively transferred NK cells to the bone marrow in patients with hematological malignancies. Blood 122, 4499 (2013).
108. Somanchi, S. S., Somanchi, A., Cooper, L. J., Lee, D. A. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 119, 5164-5172 (2012).
109. Loza, M. J., Perussia, B. The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J. Immunol. 172, 88-96 (2004).
110. Romee, R. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599-3608 (2013).
111. Boutet, P. et al. Cutting edge: the metalloproteinase ADAM17/TNF-?-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 182, 49-53 (2009).
112. Bachanova, V. et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123, 3855-3863 (2014).
113. Lopez-Verges, S. et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725-14732 (2011).
114. Elmaagacli, A. H. et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118, 1402-1412 (2011).
115. Green, M. L. et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122, 1316-1324 (2013).